Literature DB >> 7741674

Abdominal surgery in HIV/AIDS patients: indications, operative management, pathology and outcome.

M K Yii1, A Saunder, D F Scott.   

Abstract

Despite the increasing number of patients with the human immunodeficiency virus (HIV) infection, surgical experience with these patients remains limited. A retrospective review over a 9 year period (January 1985 to December 1993) was undertaken to determine the indications, operative management, pathologic findings and outcome of major abdominal surgery in these patients. A total of 51 procedures were performed in 45 patients; 30 patients had acquired immunodeficiency syndrome (AIDS) and 15 patients had asymptomatic HIV infection. Indications included gastrointestinal bleeding, complicated pancreatic pseudocysts, cholelithiasis, bowel obstruction, immune disorders, acute abdomens, elective laparotomy, colostomy formation, menorrhagia and Caesarean section. Pathologic findings directly related to the HIV infection were found in 81% of the AIDS patients and 35% of the asymptomatic HIV infected patients (P < 0.05). These included opportunistic infections, non-Hodgkin's lymphoma, Kaposi's sarcoma, immune disorders, lymphadenopathy and pancreatic pseudocysts. It was noted that AIDS patients had more complications than asymptomatic HIV infected patients with most complications related to chest problems and sepsis (61 vs 7%; P < 0.01). Emergency operations carried a higher complication rate than elective operations though this was not significant. The hospital mortality was 12%. On follow up, 13 of the 25 AIDS patients had died with the median survival of 7 months, while three of the 14 asymptomatic HIV infected patients had died with the median survival of 40 months. Of the remaining patients, the 12 AIDS patients had a median postoperative follow up of 7 months and the 11 asymptomatic HIV infected patients had a median postoperative follow up of 29.5 months.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1995        PMID: 7741674     DOI: 10.1111/j.1445-2197.1995.tb00646.x

Source DB:  PubMed          Journal:  Aust N Z J Surg        ISSN: 0004-8682


  7 in total

1.  CD4 Count is Still a Valid Indicator of Outcome in HIV-Infected Patients Undergoing Major Abdominal Surgery in the Era of Highly Active Antiretroviral Therapy.

Authors:  A Chichom-Mefire; M Azabji-Kenfack; J Atashili
Journal:  World J Surg       Date:  2015-07       Impact factor: 3.352

2.  The effect of stage of HIV disease as determined by CD4 count on clinical outcomes of surgical sepsis in South Africa.

Authors:  S Green; V Y Kong; G L Laing; J L Bruce; J Odendaal; B Sartorius; D L Clarke
Journal:  Ann R Coll Surg Engl       Date:  2017-07       Impact factor: 1.891

Review 3.  Human immunodeficiency disease: how should it affect surgical decision making?

Authors:  T E Madiba; D J J Muckart; S R Thomson
Journal:  World J Surg       Date:  2009-05       Impact factor: 3.352

Review 4.  Major liver resection for non-Hodgkin's lymphoma in an HIV-positive patient: report of a case.

Authors:  A Picciocchi; R Coppola; F Pallavicini; M E Riccioni; S Ciletti; L M Marino-Cosentino; G Marasca; L Ortona
Journal:  Surg Today       Date:  1998       Impact factor: 2.549

5.  Colorectal Surgery in Patients with HIV and AIDS: Trends and Outcomes over a 10-Year Period in the USA.

Authors:  John V Gahagan; Wissam J Halabi; Vinh Q Nguyen; Joseph C Carmichael; Alessio Pigazzi; Michael J Stamos; Steven D Mills
Journal:  J Gastrointest Surg       Date:  2016-03-03       Impact factor: 3.452

6.  The Effect of Human-Immunodeficiency Virus Status on Outcomes in Penetrating Abdominal Trauma: An Interim Analysis.

Authors:  Deidre McPherson; Valentin Neuhaus; Rohin Dhar; Sorin Edu; Andrew J Nicol; Pradeep H Navsaria
Journal:  World J Surg       Date:  2018-08       Impact factor: 3.352

Review 7.  Prevalence of HIV status and CD4 counts in a surgical cohort: their relationship to clinical outcome.

Authors:  S R Cacala; E Mafana; S R Thomson; A Smith
Journal:  Ann R Coll Surg Engl       Date:  2006-01       Impact factor: 1.891

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.